Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B1E11K
- Development stage
- Preclinical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
B1E11K is a naturally acquired human monoclonal antibody that targets glutamate-rich repetitive elements (specifically EENV repeats) found across multiple stages of the *Plasmodium falciparum* life cycle. It was identified using a target-agnostic single B cell activation method from malaria-exposed individuals. B1E11K cross-reacts with several *P. falciparum* proteins containing these repeats, including Ring-infected Erythrocyte Surface Antigen (RESA), Pf11.1, LSA3, and RESA3. Structural analysis shows that B1E11K binds to its repeating epitope motif in a head-to-head conformation, engaging in affinity-matured homotypic interactions. This antibody is being researched for its potential to block malaria transmission and prevent infection.
02
Targets
LSA-3 (Plasmodium falciparum liver-stage antigen 3)Pf11.1 (Plasmodium falciparum Pf11.1 antigen)
Beyond the preview
Go deeper on B1E11K.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B1E11K.